Cediranib
|
|
|
- CAS-Nr.
- 288383-20-0
- Englisch Name:
- Cediranib
- Synonyma:
- CS-377;AZD2171;Recentin;Cediranib;Cadiranib;NSC-732208;Cediranib R;Cediranib, >=99%;Cediranib (AZD217);Cediranib(AZD2171)
- CBNumber:
- CB3947063
- Summenformel:
- C25H27FN4O3
- Molgewicht:
- 450.51
- MOL-Datei:
- 288383-20-0.mol
|
Cediranib Eigenschaften
- Schmelzpunkt:
- 135-138°C
- Siedepunkt:
- 626.6±55.0 °C(Predicted)
- Dichte
- 1.285
- storage temp.
- Sealed in dry,Store in freezer, under -20°C
- L?slichkeit
- Acetone (Slightly), DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 16.14±0.30(Predicted)
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Cediranib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Receptors for VEGF have central roles in vasculogenesis and angiogenesis and thus serve as targets for cancer therapy. Cediranib is a potent inhibitor of VEGF receptor tyrosine kinases, including VEGFR1, 2, and 3 (IC
50s = 5, 1, and 3 nM, respectively). It also potently inhibits a variety of other receptor and non-
receptor tyrosine kinases, including several in the platelet-
derived growth factor, fibroblast growth factor, and endothelial growth factor receptor families. Cediranib blocks tubule formation by human umbilical vein endothelial cells
in vitro and prevents angiogenesis as well as xenograft tumor growth
in vivo. Because of these effects, cediranib has potential use in a range of cancers.
Verwenden
Cediranib (AZD2171) inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively.
Cediranib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Cediranib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 247)Lieferanten
288383-20-0()Verwandte Suche:
- Cediranib
- 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
- Cadiranib (AZD2171)
- Cediranib(AZD2171)
- AZD2171
- Recentin
- Cadiranib
- Cediranib R
- 4-((4-fluoro-2-Methyl-1H-indol-5-yl)oxy)-6-Methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
- Cediranib (AZD217)
- Cediranib dihydrochloride
- NSC-732208
- 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline Cediranib (AZD2171)
- Cediranib
4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
- Cediranib, >=99%
- (557795-03-6) cediranib
- RECENTIN;AZD2171;AZD 2171;AZD-2171
- CS-377
- Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-
- Cediranib (free base)
- Cediranib USP/EP/BP
- Cediranib (NSC-732208
- 288383-20-0 Cediranib
- AZD2171, Cediranib
- AZD2171|||NSC-732208
- Carprofen Impurity 8(Carprofen EP Impurity H )
- 288383-20-0
- C25H27FN4O3
- Inhibitors
- Antineoplastic
- APIs
- 288383-20-0
